Diaceutics PLC (DXRX), the precision medicine data and diagnostics commercialisation company, has disclosed that Gresham House Asset Management Ltd has increased its voting rights stake to 21.59%, up from a previously notified position of 19.01%. The threshold was crossed on 12 November 2026, with the issuer formally notified on 16 November 2026 via a TR-1 standard major holdings form filed with the FCA. The move sees Gresham House hold 18,415,527 voting rights in Diaceutics, cementing its position as a significant shareholder in the AIM-listed firm.

Key Points

  • Diaceutics PLC (DXRX) — AIM-listed precision medicine data and diagnostics commercialisation company
  • Gresham House Asset Management Ltd raised its voting rights stake in Diaceutics to 21.59%, acquiring additional shares above the previous notified level of 19.01%
  • The threshold crossing date was 12 November 2026; total voting rights now held stand at 18,415,527, all via direct shareholding under ISIN GB00BJQTGV64
  • Investors may be watching whether Gresham House continues to build its position, and what implications the increased concentration of ownership may have for future shareholder decisions

Gresham House Crosses New Threshold With 21.59% Voting Rights in Diaceutics

The TR-1 notification confirms that London-registered Gresham House Asset Management Ltd acquired or disposed of voting rights in a manner that caused its total holding to rise to 21.59% of Diaceutics PLC's voting rights. All 18,415,527 voting rights are held directly under DTR5.1, with no financial instruments such as options or contracts for difference forming part of the notified position. The announcement states that Gresham House is not controlled by any natural person or legal entity and does not control any other undertaking that itself holds an interest in Diaceutics.

Previous Notified Position of 19.01% Now Superseded Following November Transaction

Prior to this notification, Gresham House Asset Management's last disclosed position in Diaceutics stood at 19.01% of voting rights. The increase of approximately 2.58 percentage points represents a meaningful step-up in exposure to the company. The reason given for the notification is an acquisition or disposal of voting rights, indicating a direct share transaction triggered the threshold crossing. The company did not disclose the number of additional shares acquired or the consideration paid in the announcement.

Diaceutics' Precision Medicine Data Platform Attracts Continued Institutional Attention

Diaceutics PLC operates a data and commercialisation platform focused on the precision medicine sector, assisting pharmaceutical companies in improving the diagnostic testing processes that underpin targeted therapies. The company's business model centres on providing data intelligence and commercialisation services to support patient identification for precision medicines globally. Gresham House's decision to increase its stake above 21% signals sustained institutional conviction in the company's operating model, though investors should note that a highly concentrated shareholder register can itself represent a company-specific risk, particularly regarding liquidity and potential influence over corporate decisions.